



**Oxaliplatin (Eloxatin®)**  
**Revision: 2**

**Policy Number: M-0023**  
**Last Update: 6/4/2014**

Payment will not be made for any use of these drugs outside of the criteria without prior authorization. The member may not be billed unless the member explicitly agrees in writing to be responsible for the charges in accordance with the contract/provider manual. Prior authorization will only be given if the provider demonstrates the intended use meets Medicare coverage guidelines.

When appropriate compendia references the use of one of the chemotherapeutic agents listed in this Article as part of a 'combination therapy', the drug is only approved for use in such 'combinations', and the documentation should reflect, and be specific about, the use of the additional 'combination therapy' drugs.

#### **Coverage Guidelines:**

##### **FDA:**

- Colon cancer, Adjuvant, stage III, in combination with infusional 5-fluorouracil/leucovorin
- Colorectal cancer, Advanced, in combination with infusional 5-fluorouracil/leucovorin

##### **Off Label:**

- Breast cancer
- Carcinoma of stomach, Advanced/metastatic
- Colon cancer, Adjuvant stage II, in combination with 5-fluorouracil/leucovorin
- Colorectal cancer
- Colorectal cancer, Advanced, in combination with capecitabine as first-line therapy
- Esophageal cancer
- Germ cell tumor
- Metastatic colorectal cancer, First-line therapy, in combination with bevacizumab and capecitabine
- Non-Hodgkin's lymphoma
- Non-small cell lung cancer



- Ovarian cancer
- Pancreatic cancer, Advanced or metastatic, second-line therapy in combination with 5-fluorouracil and leucovorin
- Pancreatic cancer, Metastatic, first-line treatment in combination with 5-fluorouracil, leucovorin, and irinotecan

**Coding Information:**

HCPCS Code(s)

J9263	INJECTION, OXALIPLATIN, 0.5 MG
-------	--------------------------------

ICD-9 Code(s)

150.0-150.5	MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS - MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS
150.8-150.9	MALIGNANT NEOPLASM OF OTHER SPECIFIED PART OF ESOPHAGUS - MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED SITE
151.0-151.9	MALIGNANT NEOPLASM OF CARDIA - MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE
152.1	MALIGNANT NEOPLASM OF JEJUNUM
153.0-153.9	MALIGNANT NEOPLASM OF HEPATIC FLEXURE - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE
154.0-154.8	MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION - MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS
155.1	MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS
156.0-156.2	MALIGNANT NEOPLASM OF GALLBLADDER - MALIGNANT NEOPLASM OF AMPULLA OF VATER
156.8	MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS
156.9	MALIGNANT NEOPLASM OF BILIARY TRACT PART UNSPECIFIED SITE
157.0-157.9	MALIGNANT NEOPLASM OF HEAD OF PANCREAS - MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED
183.0	MALIGNANT NEOPLASM OF OVARY
183.2-183.5	MALIGNANT NEOPLASM OF FALLOPIAN TUBE - MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS
183.8	MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA

This policy has been developed for informational purposes only and constitutes neither offers of coverage nor operates as a substitute for professional healthcare advice. This document contains confidential and proprietary information of VIVA Health which may not be reproduced, distributed or printed without prior permission from VIVA Health. In addition, it contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with VIVA Health. VIVA Health makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability of the information contained herein. VIVA Health assumes no responsibility for errors or omissions contained herein or any subsequent reliance upon said information.



183.9	MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE
186.0	MALIGNANT NEOPLASM OF UNDESCENDED TESTIS
186.9	MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED TESTIS
200.30- 200.38	MARGINAL ZONE LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - MARGINAL ZONE LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.40- 200.48	MANTLE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.50- 200.58	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.60- 200.68	ANAPLASTIC LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.70- 200.78	LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.80- 200.88	OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA UNSPECIFIED SITE - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
202.01- 202.08	NODULAR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK - NODULAR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
202.80- 202.88	OTHER MALIGNANT LYMPHOMAS UNSPECIFIED SITE - OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF MULTIPLE SITES

**Background:**

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoquo and diaquo diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intra-strand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with 5-fluorouracil (5-FU), oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and L1210 (leukemia)].



### Black Box Warning:

#### **WARNING: ANAPHYLACTIC REACTIONS**

**Anaphylactic reactions to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis.**

### Definitions:

HCPCS Code—Healthcare Common Procedure Coding System - A system of letter and number codes assigned to procedures, medications, supplies and equipment used for pricing and billing.

ICD-9 Code—International Classification of Disease, 9<sup>th</sup> edition. A standardized classification of disease, injuries, and causes of death, by etiology and anatomic localization and codified into a 6-digit number, which allows clinicians, statisticians, politicians, health planners and others to speak a common language, both US and internationally.

### References:

1. Eloxatin [package insert]. Cleveland, OH: Sanofi-Aventis U.S., LLC; December 2011. Available at: <http://products.sanofi.us/eloxatin/eloxatin.html>. June 8, 2012.
2. The NCCN Drugs & Biologics Compendium™ © 2010 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed May 23, 2012.
3. Local Coverage Article for Drugs and Biologicals – Chemotherapeutic Agents (A48896) (R4). Available at: [http://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=48896&ver=89&ContrlId=213&ContrVer=1&CntrctrSelected=213\\*1&Date=01%2f01%2f2013&DocId=A48896&bc=hAAAAAaAEAAAAA%3d%3d&](http://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=48896&ver=89&ContrlId=213&ContrVer=1&CntrctrSelected=213*1&Date=01%2f01%2f2013&DocId=A48896&bc=hAAAAAaAEAAAAA%3d%3d&). Accessed June 4, 2014.
4. Micromedex® 2.0 Eloxatin. Available at: [http://www.thomsonhc.com/micromedex2/librarian/ND\\_T/evidencexpert/ND\\_PR/evidencexpert/CS/1FF9BF/ND\\_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/F3ED1E/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_P/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=eloxatin](http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/1FF9BF/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/F3ED1E/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=eloxatin) ... Accessed June 8, 2012.

### Document History:

Date Written: 6/8/12



Effective Date: 4/1/13

Revision 1: 3/19/2013

Revision 2: 6/4/2014

Internal Review: 6/11/2014

External Review: 6/17/2014

For the Archived Policy, please go

to <http://www.vivaprovider.com/Resources/CoveragePolicies.aspx> and click on the Archived Policies Link.